Merck Animal Health Receives the US FDA’s Approval for Bravecto (fluralaner) Monthly Chews to Protect Dogs and Puppies Against Fleas and Ticks

 Merck Animal Health Receives the US FDA’s Approval for Bravecto (fluralaner) Monthly Chews to Protect Dogs and Puppies Against Fleas and Ticks

Merck Animal Health Receives the US FDA’s Approval for Bravecto (fluralaner) Monthly Chews to Protect Dogs and Puppies Against Fleas and Ticks

Shots:

  • The US FDA approves Bravecto 1-month (fluralaner) chews for dogs and puppies aged≥ 8 weeks. The approval will expand Merck’s parasiticide portfolio, which are extended duration flea and tick protection products offering parasite protection for dogs
  • The product is suitable for dogs in the early stages of life to begin a regimen of monthly flea and tick protection
  • Bravecto 1-month is administered as a single, monthly flavored chew formulation for treatment and prevention of fleas and treatment and control of ticks and is expected to be available in the coming months

Click here ­to­ read full press release/ article | Ref: Merck Animal Health | Image: Merck and Chewy

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post